• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酮色林治疗创伤性血管痉挛病

Ketanserin in the treatment of traumatic vasospastic disease.

作者信息

Larsen V H, Fabricius J, Nielsen G, Hansen K S

出版信息

Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):650-2. doi: 10.1136/bmj.293.6548.650.

DOI:10.1136/bmj.293.6548.650
PMID:3092968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1341509/
Abstract

The specific serotonin receptor blocker ketanserin was given orally to 12 patients with traumatic vasospastic disease in a double blind crossover study. The effect of treatment was assessed by measuring finger systolic pressure and rewarming time after cold provocation and by medical interview and diaries. Median (range) percentage change in finger systolic pressure after cooling was 50 (0-100)% after treatment with ketanserin compared with 0 (0-90)% after placebo. Median (range) rewarming time after cooling decreased from 320 (236-972)s with placebo to 160 (88-404)s after treatment with ketanserin. These changes were not significant. Ninety five percent confidence intervals for difference between the treatments, however, showed that finger systolic pressure may be 80% better and rewarming time 256 seconds faster after treatment with ketanserin than after placebo. The number of attacks did not differ significantly between the two treatments. Two patients had a feeling of warmth in their hands during treatment with ketanserin. The results suggest that orally administered ketanserin may improve digital circulation in patients with traumatic vasospastic disease, but larger numbers of patients are required to assess the true effect of treatment with ketanserin in this disease.

摘要

在一项双盲交叉研究中,对12名创伤性血管痉挛疾病患者口服特异性血清素受体阻滞剂酮色林。通过测量冷刺激后的手指收缩压和复温时间、医学访谈及日记来评估治疗效果。与服用安慰剂后相比,服用酮色林后冷却后手指收缩压的中位数(范围)变化百分比为50(0 - 100)%,而服用安慰剂后为0(0 - 90)%。冷却后的复温时间中位数(范围)从服用安慰剂后的320(236 - 972)秒降至服用酮色林后的160(88 - 404)秒。这些变化无显著意义。然而,两种治疗之间差异的95%置信区间显示,服用酮色林后手指收缩压可能比服用安慰剂后改善80%,复温时间快256秒。两种治疗之间发作次数无显著差异。两名患者在服用酮色林治疗期间手部有温暖感。结果表明,口服酮色林可能改善创伤性血管痉挛疾病患者的手指血液循环,但需要更多患者来评估酮色林治疗该疾病的真实效果。

相似文献

1
Ketanserin in the treatment of traumatic vasospastic disease.酮色林治疗创伤性血管痉挛病
Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):650-2. doi: 10.1136/bmj.293.6548.650.
2
The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.酮色林治疗原发性雷诺现象患者的有效性。一项随机、双盲、安慰剂对照研究。
Int Angiol. 1987 Jul-Sep;6(3):313-22.
3
International study of ketanserin in Raynaud's phenomenon.酮色林治疗雷诺现象的国际研究。
Am J Med. 1989 Sep;87(3):264-8. doi: 10.1016/s0002-9343(89)80148-2.
4
Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.酮色林对原发性雷诺现象患者影响的定量研究。一项随机、双盲、安慰剂对照研究以及一项额外的长期开放试验。
Microcirc Endothelium Lymphatics. 1985;2(6):657-85.
5
Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.长期服用酮色林对雷诺现象患者5-羟色胺水平、血小板聚集及外周循环的影响。一项双盲、安慰剂对照的交叉研究。
Int Angiol. 1988 Jan-Mar;7(1):19-25.
6
The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.选择性5-羟色胺S2受体拮抗剂酮色林在雷诺现象治疗中的应用。
Eur J Vasc Surg. 1988 Dec;2(6):371-5. doi: 10.1016/s0950-821x(88)80014-8.
7
Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.酮色林治疗与系统性硬皮病相关的雷诺现象。
Br J Dermatol. 1988 Dec;119(6):751-4. doi: 10.1111/j.1365-2133.1988.tb03498.x.
8
Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.酮色林对进行性系统性硬化症中雷诺现象的影响:一项双盲试验。
Drugs Exp Clin Res. 1985;11(9):659-63.
9
Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.用酮色林治疗结缔组织病患者的雷诺现象。
Br Med J (Clin Res Ed). 1984 Sep 8;289(6445):577-9. doi: 10.1136/bmj.289.6445.577.
10
Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.酮色林与己酮可可碱治疗雷诺现象的疗效比较
Angiology. 1989 Jul;40(7):633-8. doi: 10.1177/000331978904000705.

引用本文的文献

1
Diagnostic tests in Raynaud's phenomena in workers exposed to vibration: a comparative study.接触振动的工人雷诺现象的诊断测试:一项比较研究。
Br J Ind Med. 1988 Jun;45(6):426-30. doi: 10.1136/oem.45.6.426.

本文引用的文献

1
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.使用5-羟色胺2受体拮抗剂酮色林治疗雷诺现象。
Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.
2
Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.用酮色林治疗结缔组织病患者的雷诺现象。
Br Med J (Clin Res Ed). 1984 Sep 8;289(6445):577-9. doi: 10.1136/bmj.289.6445.577.
3
Raynaud syndrome.雷诺综合征
Semin Arthritis Rheum. 1981 May;10(4):282-308. doi: 10.1016/0049-0172(81)90006-8.
4
Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size.临床生物统计学。第三十四部分:“统计学显著性”的另一面:α、β、δ与样本量的计算。
Clin Pharmacol Ther. 1975 Oct;18(4):491-505. doi: 10.1002/cpt1975184491.
5
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.β错误、II型错误以及样本量在随机对照试验设计与解读中的重要性。对71项“阴性”试验的调查。
N Engl J Med. 1978 Sep 28;299(13):690-4. doi: 10.1056/NEJM197809282991304.